文献速递帕金森病与运动障碍神经免疫

抗肿瘤坏死因子治疗与炎症性肠病患者帕金森病发病率

Anti-Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease.
PubMed 文献 · JAMA Neurol · 2018-01-01

这项回顾性队列研究分析2000年1月1日至2016年3月31日Truven Health MarketScan行政索赔数据库和Medicare补充数据库,纳入144 018例炎症性肠病(IBD)患者并按年龄、性别和索引日期年份匹配720 090名无IBD对照。IBD患者帕金森病(PD)发病率较对照高28%(校正发病率比1.28,95%CI 1.14-1.44,P<.001);接受抗肿瘤坏死因子(anti-TNF)治疗的IBD患者PD发病率较未暴露者降低78%(校正发病率比0.22,95%CI 0.05-0.88,P=.03)。

要点

  • IBD患者PD发病率较无IBD匹配对照高28%(校正发病率比1.28,95%CI 1.14-1.44,P<.001)。
  • 接受anti-TNF治疗的IBD患者PD发病率较未暴露者降低78%(校正发病率比0.22,95%CI 0.05-0.88,P=.03)。
  • 作者认为上述发现支持全身性炎症在两种疾病发病机制中的作用,需进一步研究抗TNF治疗能否降低高危个体PD风险。

核心结论

  • IBD患者中观察到PD发病率高于无IBD个体。
  • 早期暴露于抗炎性anti-TNF治疗与PD发病率大幅降低相关。
  • 这些发现支持全身性炎症在两种疾病发病机制中的作用。
  • 需进一步研究以确定对高危个体给予抗TNF治疗是否可减轻PD风险。

研究设计与样本

  • 回顾性队列研究,分析2000年1月1日至2016年3月31日Truven Health MarketScan行政索赔数据库和Medicare补充数据库中的信息。
  • 纳入标准为至少有2条IBD诊断索赔、至少6个月随访、且在IBD索引日期当日或之前无PD诊断的个体。
  • 共纳入144 018例IBD患者,按年龄、性别和索引日期年份与720 090名无IBD对照匹配。
  • anti-TNF暴露从anti-TNF索引日期测量至anti-TNF覆盖最后日期、入组结束或PD索引日期三者中最早者。
  • 计算每1000人年的发病率,采用Poisson回归模型估计粗率和校正发病率比并以95%CI呈现。

主要发现

  • 144 018例IBD患者中,1796例至少有2次PD诊断和至少1张PD相关处方。
  • IBD患者平均(SD)年龄为51(17)岁,44%为男性。
  • IBD患者PD发病率较无IBD匹配对照高28%(校正发病率比1.28,95%CI 1.14-1.44,P<.001)。
  • 接受anti-TNF治疗的IBD患者PD发病率较未暴露者降低78%(校正发病率比0.22,95%CI 0.05-0.88,P=.03)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需进一步研究以确定对高危个体给予抗TNF治疗是否可减轻PD风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Despite established genetic and pathophysiologic links between inflammatory bowel disease (IBD) and Parkinson disease (PD), clinical data supporting this association remain scarce. Although systemic inflammation is considered a potential biological mechanism shared between the 2 diseases, the role of reduced systemic inflammation through IBD-directed anti-tumor necrosis factor (anti-TNF) therapy in PD risk is largely unknown. OBJECTIVE: To compare the incidence of PD among individuals with or without IBD and to assess whether PD risk among patients with IBD is altered by anti-TNF therapy. DESIGN, SETTING, AND PARTICIPANTS: This is a retrospective cohort study analyzing information in the Truven Health MarketScan administrative claims database and the Medicare Supplemental Database between January 1, 2000, and March 31, 2016. Individuals were selected who had at least 2 claims for IBD diagnoses, at least 6 months of follow-up, and no prior diagnosis of PD on or before the IBD index date. Exposure to Anti-TNF therapy was measured from the anti-TNF index date to the last date of anti-TNF coverage or the end of enrollment or PD index date, whichever was earliest. Incidence rates per 1000 person-years were calculated, and crude and adjusted incidence rate ratios were estimated by Poisson regression models and presented with 95% CIs. MAIN OUTCOMES AND MEASURES: Incidence of PD among patients with IBD with or without exposure to anti-TNF therapy. RESULTS: In total, 144 018 individuals with IBD were matched on age, sex, and year of index date with 720 090 unaffected controls. Of them, 1796 individuals had at least 2 PD diagnoses and at least 1 filled PD-related prescription. The mean (SD) age of individuals with IBD was 51 (17) years, and 44% were men. The incidence of PD among patients with IBD was 28% higher than that among unaffected matched controls (adjusted incidence rate ratio, 1.28; 95% CI, 1.14-1.44; P < .001). A 78% reduction in the incidence rate of PD was detected among patients with IBD who were exposed to anti-TNF therapy compared with those who were not exposed (adjusted incidence rate ratio, 0.22; 95% CI, 0.05-0.88; P = .03). CONCLUSIONS AND RELEVANCE: A higher incidence of PD was observed among patients with IBD than among individuals without IBD. Early exposure to antiinflammatory anti-TNF therapy was associated with substantially reduced PD incidence. These findings support a role of systemic inflammation in the pathogenesis of both diseases. Further studies are required to determine whether anti-TNF treatment administered to high-risk individuals may mitigate PD risk.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Peter I, Dubinsky M, Bressman S, et al. Anti-Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease. JAMA Neurol. 2018. PMID: 29710331. doi:10.1001/jamaneurol.2018.0605

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。